Unilever Jumps After Nelson Peltz Joins Board

Zinger Key Points
  • Investors are hoping Peltz can help unlock value in the struggling stock, which has dropped over 22% in three years.
  • Peltz has previously served on the boards of consumer goods companies Procter & Gamble and Kraft Heinz.

Unilever plc UL shares traded higher by 8% on Tuesday after the company announced activist investor Nelson Peltz is joining the company's board of directors.

What Happened? On Tuesday morning, Unilever named Peltz a board member and non-executive director. Peltz will serve as a member of the board's compensation committee and work with the company on business strategy. Pelz's hedge fund Trian Fund Management also has a 1.5% ownership stake in Unilever.

Related Link: Q1 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios

Why It's Important: In a statement, Unilever Chair Nils Anderson said the company has been working closely with Peltz since Trian first took a stake in Unilever several months ago.

“We look forward to working collaboratively with management and the Board to help drive Unilever’s strategy, operations, sustainability, and shareholder value,” Peltz said in a statement.

Investors are hoping Peltz can help unlock value in the struggling stock, which is down 22.6% overall in the past three years.

Unilever's management has been under fire since GSK plc GSK rejected Unilever's unsolicited $68.4 billion buyout offer for GSK's consumer healthcare goods unit in January. GSK said at the time that it had rejected a series of three bids from Unilever that the company believed "fundamentally undervalued" its consumer healthcare goods unit.

Peltz has previously served on the boards of consumer goods companies Procter & Gamble Co PG, Kraft Heinz Co KHC and MONDELEZ INTERNATIONAL INC MDLZ. At least two other large Unilever shareholders reportedly pressured the company to add Peltz to the board, according to the Wall Street Journal.

Benzinga's Take: Considering Unilever's slumping sales, lagging share price and inability to close its GSK deal, investors don't have much to lose with Peltz on board. It's unclear what, if anything, Peltz can do to right the ship in the near-term, but the market seems optimistic he'll come up with something to unlock value in the stock.

Posted In: Nelson PeltzNils AndersonTrian Fund ManagementNewsHedge FundsManagementGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.